Sugi Predict

Sugi Predict / Compounds / SCHEMBL240574

SCHEMBL240574

SCHEMBL240574

O=[N+]([O-])c1c(F)cccc1F

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 4/20 0.52
▸ ALDH1A1 P00352 3/20 0.52
▸ TSHR P16473 2/20 0.45
▸ GPR35 Q9HC97 2/20 0.45
▸ LMNA P02545 2/20 0.44
▸ CYP3A4 P08684 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ MAPT P10636 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ S100A4 P26447 1/20 0.40
▸ HIF1A Q16665 1/20 0.40
▸ CES2 O00748 1/20 0.39
▸ CES1 P23141 1/20 0.39
▸ HSPB1 P04792 2/20 0.38
▸ VCAM1 P19320 1/20 0.38
▸ MGMT P16455 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2843518 0.86 TDP1 (0.45) TDP1ALDH1A1TSHRGPR35LMNA
SCHEMBL98247 0.86 GPR35 (0.59) TDP1ALDH1A1TSHRGPR35ATM
SCHEMBL29557370 0.86 GPR35 (0.59) TDP1ALDH1A1TSHRGPR35ATM
SCHEMBL550845 0.84 ALDH1A1 (0.43) TDP1ALDH1A1TSHRGPR35LMNA
SCHEMBL418362 0.84 TDP1 (0.43) TDP1ALDH1A1TSHRGPR35LMNA
SCHEMBL31050080 0.84 ALDH1A1 (0.43) TDP1ALDH1A1TSHRGPR35LMNA
SCHEMBL240809 0.84 ALDH1A1 (0.43) TDP1ALDH1A1TSHRGPR35LMNA
SCHEMBL5851 0.84 ALDH1A1 (0.72) TDP1ALDH1A1TSHRCYP3A4MAPT
SCHEMBL16955036 0.84 TDP1 (0.43) TDP1ALDH1A1TSHRGPR35LMNA
SCHEMBL30267557 0.84 TDP1 (0.43) TDP1ALDH1A1TSHRGPR35LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117288860-A Analysis method of genotoxic impurities in flurbiprofen 湖南九典宏阳制药有限公司 2023-12-26 — — CN claimed
CN-110632199-B Method for simultaneously determining content of coexisting impurities in 2, 4-difluoroaniline 天地恒一制药股份有限公司 2022-08-16 — — CN claimed
CN-112010904-B Benzimidazole diphosphine Cu (I) complex and preparation method thereof 洛阳理工学院 2021-07-20 — — CN claimed
CN-112010904-A Benzimidazole diphosphine Cu (I) complex and preparation method thereof 洛阳理工学院 2020-12-01 — — CN claimed
CN-110632199-A Method for simultaneously determining content of coexisting impurities in 2, 4-difluoroaniline 天地恒一制药股份有限公司 2019-12-31 — — CN claimed
CN-104219954-B Benzamide derivatives 翻译基因组学研究院 2017-03-22 — — CN claimed
US-20160362382-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL DRUG DEVELOPMENT, LLC 2016-12-15 — — US claimed
US-9464059-B2 Benzamide derivatives THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2016-10-11 — — US claimed
US-20150284336-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL DRUG DEVELOPMENT, LLC 2015-10-08 — — US claimed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 — — US claimed
EP-2445345-B1 BENZAMIDE DERIVATIVES TRANSLATIONAL GENOMICS RES INST (US) 2014-08-27 — — EP claimed
US-20120142922-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2012-06-07 — — US claimed
EP-2445345-A1 BENZAMIDE DERIVATIVES The Translational Genomics Research Institute (US) 2012-05-02 — — EP claimed
WO-2010151441-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2010-12-29 — — WO claimed
EP-4747260-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-27 — — EP disclosed
WO-2026103873-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF 杭州百新生物医药科技有限公司 2026-05-21 — — WO disclosed
EP-4743447-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2026-05-20 — — EP disclosed
US-4138567-A HYPOTENSIVE AMERICAN HOME PRODUCTS CORPORATION (US) 1979-02-06 — — US disclosed
US-4089958-A HYPOTENSIVE AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1978-05-16 — — US disclosed
US-4032639-A 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2-a,]quinoxalin-5(6H)-ones and derivatives thereof for relieving hypertension AMERICAN HOME PRODUCTS CORPORATION (US) 1977-06-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142922-A1 BENZAMIDE DERIVATIVES BRDT, BRD3, BRD2 TDP1 2301/4885ALDH1A1 592/4885TSHR 3508/4885
US-20150284336-A1 BENZAMIDE DERIVATIVES BRDT, BRD3, BRD2 TDP1 2301/4885ALDH1A1 592/4885TSHR 3508/4885
US-20160362382-A1 BENZAMIDE DERIVATIVES BRDT, BRD3, BRD2 TDP1 2301/4885ALDH1A1 592/4885TSHR 3508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.